![logo](/logos/STRO.webp)
Sutro Biopharma, Inc.
NASDAQ:STRO
4.12 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Sutro Biopharma, Inc. |
Symbool | STRO |
Munteenheid | USD |
Prijs | 4.12 |
Beurswaarde | 337,690,444 |
Dividendpercentage | 0% |
52-weken bereik | 2.01 - 6.13 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. William J. Newell J.D. |
Website | https://www.sutrobio.com |
An error occurred while fetching data.
Over Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)